TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11802678

Group type: EXPERIMENTAL
Intervention: HR feedback training (FB+)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (FB-)
Number of subjects: 25
Study: 9566995

Group type: EXPERIMENTAL
Intervention: Full-fat rice bran (84 g/d)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Oat bran (84 g/d)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Rice starch placebo
Number of subjects: 44
Study: 8281622

Group type: EXPERIMENTAL
Intervention: Tropisetron
Number of subjects: 66

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 66
Study: 1698846

Group type: EXPERIMENTAL
Intervention: In vitro reactivity and sensitivity of basophils to antigen for histamine release
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combination of basophil, antigen, histamine, and codeine skin sensitivity and reactivity
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Antigen sensitivity, basophil and mast cell reactivity, and end organ responsiveness to mediators
Number of subjects: 22
Study: 1273734

Group type: EXPERIMENTAL
Intervention: 0.5 mg of oral PGE2 given hourly
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Doubling the dose of oral PGE2 hourly, starting with 0.5 mg and increasing to a maximum of 2.0 mg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Both regimens of oral PGE2
Number of subjects: 37
Study: 31600429

Group type: EXPERIMENTAL
Intervention: 3-month structured exercise intervention (n=21)
Number of subjects: 31

Group type: COMPARATOR
Intervention: 3-month waitlist control (n=10)
Number of subjects: 31
Study: 31326270

Group type: EXPERIMENTAL
Intervention: FRESH score
Number of subjects: 107
Study: 28188965

Group type: EXPERIMENTAL
Intervention: Zinc sulfate (ZS) 220-mg capsules (50 mg elemental zinc) from the 16th day of the menstrual cycle to the second day of the next cycle
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 25605632

Group type: EXPERIMENTAL
Intervention: Feedback group (n = 29)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (n = 28)
Number of subjects: 57
Study: 23212438

Group type: EXPERIMENTAL
Intervention: Active bupropion
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo bupropion
Number of subjects: 416
Study: 16796081

Group type: EXPERIMENTAL
Intervention: Psychoeducation group program (n=46)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Regular treatment group (n=35)
Number of subjects: 81
Study: 12489980

Group type: EXPERIMENTAL
Intervention: Lacidipine 2 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lacidipine 6 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lacidipine 8 mg (single dose)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lacidipine (repeated doses of 2-6 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lacidipine (single and repeated doses)
Number of subjects: 24
Study: 10474139

Group type: EXPERIMENTAL
Intervention: Repeated confidence intervals for a parameter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General results in Hu and Lagakos
Number of subjects: 0
Study: 8901152

Group type: EXPERIMENTAL
Intervention: Flupirtine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tetrazepam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2004545

Group type: EXPERIMENTAL
Intervention: sulodexide
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 6184780

Group type: EXPERIMENTAL
Intervention: Alpha-amylase inhibitor
Number of subjects: 6
Study: 31785251

Group type: EXPERIMENTAL
Intervention: Voxel-based 3D analyses
Number of subjects: 15

Group type: COMPARATOR
Intervention: Landmark-based cephalometric analyses
Number of subjects: 15
Study: 31077640

Group type: EXPERIMENTAL
Intervention: Peanut Ball (PB)
Number of subjects: 343
Study: 27927064

Group type: EXPERIMENTAL
Intervention: Yingliu mixture combined with methimazole (Y-M), orally administered 25 mL three times daily for 12 weeks.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Methimazole alone, administered at 5-25 mg/day for 12 weeks.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups (Y-M and methimazole)
Number of subjects: 120
Study: 26004591

Group type: EXPERIMENTAL
Intervention: Water delivery
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional delivery
Number of subjects: 120
Study: 24460309

Group type: EXPERIMENTAL
Intervention: Microwave hyperthermia combined with cisplatin chemotherapy and radiotherapy
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Microwave hyperthermia with T90 < 43°
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Microwave hyperthermia performed 4-10 times
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Microwave hyperthermia before or after radiotherapy
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (cisplatin chemotherapy and radiotherapy only)
Number of subjects: 154
Study: 22263332

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone (P2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone (P1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (P3)
Number of subjects: 60
Study: 19695548

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 198
Study: 16996857

Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg twice daily
Number of subjects: 705

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 705
Study: 12699209

Group type: EXPERIMENTAL
Intervention: Subjective measures (visual analog scales)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Objective measures (peak expiratory flow rates)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sociodemographic features (poor and minority families)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Children's symptom accuracy
Number of subjects: 100
Study: 10929034

Group type: EXPERIMENTAL
Intervention: Induction therapy (ROAD-IN) consisting of ranimustine, vincristine, melphalan, dexamethasone, and interferon alpha (IFN-alpha) administered three times weekly for 3 weeks starting on day 22, repeated for three cycles.
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Responders (CR + PR) to induction therapy.
Number of subjects: 161

Group type: COMPARATOR
Intervention: Interferon alpha (IFN-alpha) maintenance therapy.
Number of subjects: 161

Group type: COMPARATOR
Intervention: Non-responders to induction therapy.
Number of subjects: 161
Study: 8985622

Group type: EXPERIMENTAL
Intervention: Tilt to 90 degrees for 10 min (orthostatic hypotension)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Tilt to 90 degrees for 10 min (orthostatic tachycardia plus)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Tilt to 90 degrees for 30 min (vasovagal syncope)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Tilt to 60 degrees, 80 degrees, and 90 degrees for 20 min
Number of subjects: 86
Study: 1458672

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (400 mg/kg by i.v. infusion over 3 h)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (albumen and sucrose by similar infusion)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin and Placebo
Number of subjects: 31
Study: 6747036

Group type: EXPERIMENTAL
Intervention: Two week program involving perspective-taking of social entities (friend, family, peer group, society)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Revised identity scale with discrepancy score measure
Number of subjects: 87
Study: 30288761

Group type: EXPERIMENTAL
Intervention: Zero-Balance Ultrafiltration (Z-BUF) of priming blood
Number of subjects: 60
Study: 29716192

Group type: EXPERIMENTAL
Intervention: Soybean oil
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Palm oil
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Camellia oil
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tallow
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control without oils
Number of subjects: 15
Study: 27548794

Group type: EXPERIMENTAL
Intervention: Caffeine 1.5 mg·kg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Caffeine 3.0 mg·kg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Caffeine 6.0 mg·kg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Caffeine (various doses)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Caffeine 7.5 mg·kg
Number of subjects: 13
Study: 24586912

Group type: EXPERIMENTAL
Intervention: RUTI vaccine (25 µg)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: RUTI vaccine (5 µg)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: RUTI vaccine (50 µg)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 21719717

Group type: EXPERIMENTAL
Intervention: ONO-5334 100 mg once daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ONO-5334 300 mg once daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ONO-5334 600 mg once daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ONO-5334 100 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ONO-5334 300 mg and 600 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ONO-5334 (various doses)
Number of subjects: 120
Study: 19926400

Group type: EXPERIMENTAL
Intervention: Naltrexone (32 mg/day) and bupropion (360 mg/day) plus behavioral counseling
Number of subjects: 30
Study: 16930857

Group type: EXPERIMENTAL
Intervention: Tiagabine 24 mg/day
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Gabapentin 2400 mg/day
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 16231757

Group type: EXPERIMENTAL
Intervention: Strict treatment to maintain systolic BP below 140 mmHg (group A)
Number of subjects: 4320

Group type: COMPARATOR
Intervention: Mild treatment to maintain systolic BP between 140 and below 160 mmHg (group B)
Number of subjects: 4320

Group type: EXPERIMENTAL
Intervention: Primary endpoints (stroke, cardiac disease, vascular disease, renal failure)
Number of subjects: 4320
Study: 11973014

Group type: EXPERIMENTAL
Intervention: Placebo administration with painful stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo effects established on remembered pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal expectancy for drug efficacy and individual differences in suggestibility
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent pain intensity and unpleasantness
Number of subjects: 0
Study: 9989684

Group type: EXPERIMENTAL
Intervention: Test supplement (wheat fiber and protein)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Positive control (American Association of Cereal Chemists wheat bran supplement)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Negative control (1.7 g fiber/d)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Test supplement
Number of subjects: 24
Study: 7479629

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program (weight loss, reduced sodium and alcohol intake, increased physical activity)
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program
Number of subjects: 902
Study: 2258026

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDCA) at dosage of 15 mg/kg/daily
Number of subjects: 112

Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (UDCA) at dosage of 15 mg/kg/daily
Number of subjects: 112
Study: 6998389

Group type: EXPERIMENTAL
Intervention: Radical peritoneal debridement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard surgical management
Number of subjects: 0
Study: 31134315

Group type: EXPERIMENTAL
Intervention: Radiographic signs of hook of hamate fracture
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ring sign
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Oblique view
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lateral view
Number of subjects: 50
Study: 29854166

Group type: EXPERIMENTAL
Intervention: Clinical Case Demand Index (CCDI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing workload measures
Number of subjects: 0
Study: 25475901

Group type: EXPERIMENTAL
Intervention: 50 VR colonoscopies (group I)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 100 VR colonoscopies (group II)
Number of subjects: 18
Study: 23132875

Group type: EXPERIMENTAL
Intervention: Health education programme 'Ready to Act' (12-week programme including 2 one-to-one and 8 group sessions, 18 hours total)
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Health education programme 'Ready to Act'
Number of subjects: 509

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 509
Study: 21501336

Group type: EXPERIMENTAL
Intervention: 40mg oral baclofen
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 18984660

Group type: EXPERIMENTAL
Intervention: Testosterone supplementation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Recombinant human IGF‐I injections
Number of subjects: 24
Study: 17303495

Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg plus sublingual misoprostol 600 microg before D&E
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg plus vaginal misoprostol 600 microg before D&E
Number of subjects: 900

Group type: COMPARATOR
Intervention: Sublingual misoprostol 600 microg before D&E
Number of subjects: 900

Group type: COMPARATOR
Intervention: Vaginal misoprostol 600 microg before D&E
Number of subjects: 900
Study: 15079132

Group type: EXPERIMENTAL
Intervention: Controlled hypotension induced by thoracic epidural anaesthesia (Group T)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Endotracheal anesthesia (Group K)
Number of subjects: 36
Study: 11796079

Group type: EXPERIMENTAL
Intervention: 8 sessions of group music therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no group music therapy)
Number of subjects: 18
Study: 9401647

Group type: EXPERIMENTAL
Intervention: Oral glucose loading
Number of subjects: 0
Study: 8017669

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with hyperbaric bupivacaine 0.5% (0.08 mg.cm‐1 of height)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia with a bolus dose of 0.5% plain bupivacaine followed by continuous infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 20
Study: 3320184

Group type: EXPERIMENTAL
Intervention: ICI 118551
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 11
Study: 31360882

Group type: EXPERIMENTAL
Intervention: Personalized breast cancer screening (biannually, annually, biennially, or not at all depending on risk and age)
Number of subjects: 65000

Group type: COMPARATOR
Intervention: Annual breast cancer screening
Number of subjects: 65000
Study: 27570089

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg oral daily
Number of subjects: 116

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 116
Study: 25344270

Group type: EXPERIMENTAL
Intervention: Hypoxia (12% O2)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Normoxia (21% O2)
Number of subjects: 11
Study: 22104960

Group type: EXPERIMENTAL
Intervention: 80 kVp with MC‐CM (70 mL of 300 mgI/mL)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 120 kVp with HC‐CM (70 mL of 370 mg iodine/mL)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 80 kVp with MC‐CM
Number of subjects: 90
Study: 21432599

Group type: EXPERIMENTAL
Intervention: Minimal breakfast
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard breakfast
Number of subjects: 150
Study: 18457338

Group type: EXPERIMENTAL
Intervention: Monthly maintenance Interpersonal Psychotherapy (IPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive clinical management (CM)
Number of subjects: 0
Study: 16156350

Group type: EXPERIMENTAL
Intervention: New spatio-temporal elastic registration algorithm for motion reconstruction from ultrasound sequences.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous method based on pairwise registration of consecutive frames.
Number of subjects: 0
Study: 12757993

Group type: EXPERIMENTAL
Intervention: Understanding of clinical equipoise and its acceptance
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Understanding of randomization principles (chance and comparison)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Belief in clinical equipoise
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Trial information provision
Number of subjects: 21
Study: 10491544

Group type: EXPERIMENTAL
Intervention: Multiple-agent chemotherapy and irradiation to the primary tumor volume
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Growth hormone injections
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Reconstructive surgery
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 213
Study: 8946439

Group type: COMPARATOR
Intervention: Fluoxetine 40 mg and placebo (Group I, n = 13)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg plus dexfenfluramine 15 mg at night (Group II, n = 20)
Number of subjects: 33
Study: 1934527

Group type: EXPERIMENTAL
Intervention: Clonidine (300 micrograms, orally)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of GRF 1‐29 (0.3 micrograms/kg/h)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Clonidine pretreatment with GRF infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6285533

Group type: EXPERIMENTAL
Intervention: Cyclosporin A plus prednisone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard immunosuppressive therapy (antilymphoblast globulin, prednisone, and azathioprine)
Number of subjects: 100
Study: 6695663

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control exercise tests on days 1 and 2
Number of subjects: 23
Study: 29170030

Group type: EXPERIMENTAL
Intervention: $2 incentive
Number of subjects: 1688

Group type: EXPERIMENTAL
Intervention: Lottery participation
Number of subjects: 1688

Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 1688
Study: 26910672

Group type: EXPERIMENTAL
Intervention: Hand-based thermoplastic splint
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ulnar gutter splint
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 24189519

Group type: EXPERIMENTAL
Intervention: Hemofilter
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control
Number of subjects: 159
Study: 22327574

Group type: EXPERIMENTAL
Intervention: 0.5% TC
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 0.75% TC
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 0.75% EG
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 1% EG
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: EG supplementation
Number of subjects: 75

Group type: COMPARATOR
Intervention: Negative control (‐ve S. Enteritidis, ‐ve TC, or EG)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Compound control (‐ve S. Enteritidis, +ve 0.75% TC or 1% EG)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Positive control (+ve S. Enteritidis, ‐ve TC, or EG)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Low-dose treatment (+ve S. Enteritidis, +ve 0.5% TC, or 0.75% EG)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High-dose treatment (+ve S. Enteritidis, +ve 0.75% TC, or 1% EG)
Number of subjects: 75
Study: 19793085

Group type: EXPERIMENTAL
Intervention: Usual care with additional allergen and trigger identification and avoidance advice
Number of subjects: 214

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 214
Study: 18553245

Group type: EXPERIMENTAL
Intervention: Medically occupationally orientated rehabilitation (MBO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard medical rehabilitation
Number of subjects: 0
Study: 16293966

Group type: EXPERIMENTAL
Intervention: Pylorus-preserving Kausch-Whipple (PP-KW)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Standard Kausch-Whipple (KW)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Post-operative complications
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 550
Study: 12095484

Group type: EXPERIMENTAL
Intervention: Intracervical insemination samples
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination samples
Number of subjects: 75
Study: 10673878

Group type: EXPERIMENTAL
Intervention: Tropisetron 0.1 mg kg‐1 to a maximum of 5 mg
Number of subjects: 58

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 58
Study: 8766474

Group type: EXPERIMENTAL
Intervention: Autoperfusion balloon PTCA
Number of subjects: 158

Group type: COMPARATOR
Intervention: Conventional PTCA
Number of subjects: 158
Study: 1918581

Group type: EXPERIMENTAL
Intervention: Propranolol (80 or 120 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 7249345

Group type: EXPERIMENTAL
Intervention: one puff in each nostril four times daily
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: two puffs in each nostril twice daily
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: four puffs in each nostril once per day
Number of subjects: 123
Study: 30465137

Group type: EXPERIMENTAL
Intervention: Effervescent calcium magnesium citrate (EffCaMgCit)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Calcium acetate (CaAc)
Number of subjects: 18
Study: 29093152

Group type: EXPERIMENTAL
Intervention: Pomalidomide (POM)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 23
Study: 27544837

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 25019571

Group type: EXPERIMENTAL
Intervention: Brivanib 800 mg orally every day until disease progression or prohibitive toxicity
Number of subjects: 45
Study: 22110164

Group type: EXPERIMENTAL
Intervention: Timolol 0.5% solution
Number of subjects: 28

Group type: COMPARATOR
Intervention: Timolol 0.1% hydrogel
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both timolol formulations
Number of subjects: 28